
Naveen Pemmaraju/mdanderson.org
Mar 11, 2025, 08:03
Naveen Pemmaraju: Bromodomain and PLX51107 with Azacitidine in Patients with R/R Myeloid Malignancies
Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center, shared a paper he and his colleagues authored on X:
“Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.”
Authors: Jayastu Senapati et al.
cancer
Courtney D. DiNardo
Darla Miller
Elias Jabbour
Farhad Ravandi
Gautam Borthakur
Ghayas C. Issa
Guillermo Garcia-Manero
Jan Burger
Jayastu Senapati
Joseph D. Khoury
Kapil N. Bhalla
Koji Sasaki
Lucia Masarova
Marina Konopleva
Nathaniel R. Wilson
Naval Daver
Naveen Pemmaraju
Nicholas J. Short
Nitin Jain
OncoDaily
Oncology
Sherry Pierce
Tapan Kadia
Warren C. Fiskus
Wei Qiao
Yesid Alvarado
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 11, 2025, 16:48
Mar 11, 2025, 16:33
Mar 11, 2025, 16:24
Mar 11, 2025, 15:02
Mar 11, 2025, 14:44
Mar 11, 2025, 14:12
Mar 11, 2025, 13:57